• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Research Participation FAQs


What is the difference between Alzheimer’s disease and Alzheimer’s dementia?

When we talk about Alzheimer’s disease we mean the changes in the brain that may lead to Alzheimer’s dementia. An individual can have signs of Alzheimer’s disease in the brain without having Alzheimer’s dementia. Alzheimer’s disease may develop into Alzheimer’s dementia, but does not always do so. Alzheimer’s dementia refers to the clinical syndrome where memory and thinking are impaired to the extent that day-to-day functioning of the individual is affected.


What is an MRI brain scan?

Magnetic Resonance Imaging (MRI) is an established, widely accepted medical way to look in detail at the structure of the brain. MRI is painless, but participants will need to lie still in the scanner for up to 80 minutes and some people can find this claustrophobic. The scanner is also quite noisy, although participants will be wearing ear protection.


What happened during the clinical examination?

The examination included measurement of blood pressure, height, weight, hip and waist circumference. The study doctor also did a full neurological (senses, power, coordination and reflexes) and cardiac examination. Participants were also be asked to provide information about medical history, including family history of dementia, and their current medication(s).

The physical examination was conducted annually while participants were enrolled in the EPAD cohort.


What happened during the cognitive assessments?

The cognitive assessments were undertaken using a neuropsychological examination assessing reaction time, function, language skills, memory and attention by means of several tests. The study psychologist or research nurse provided clear instructions on how to complete the assessments.

The cognitive tests were conducted at the initial study visit, after six months, and then annually, while participants were enrolled in the EPAD cohort.


How was spinal fluid collected?

Spinal fluid was collected with a procedure called a lumbar puncture. The spinal fluid connects with the spaces within and around the brain so is a very good source of information about what is happening in the brain. This is a commonly conducted test in both research and clinical practice in many parts of Europe.

The procedure takes about an hour in total. Participants are normally be lying on their side, with their legs pulled up and their chin tucked in, but the procedure can also be carried out while they are seated and leaning forwards. Under local anaesthetic, approximately 10 ml of spinal fluid is collected. The lumbar puncture usually takes around 30-45 minutes to complete. After the procedure participants are asked to rest for approximately 30 minutes.

The spinal fluid sample were taken annually while participants were enrolled in the EPAD cohort.


Who was funding and organising this research?

The research was organised in several European countries under the leadership of the University of Edinburgh, Scotland, UK. EPAD was funded by the European Commission and the European Federation of the Pharmaceutical Industry Association (EFPIA) through the Innovative Medicines Initiative Joint Undertaking (IMI JU).


Share this page
FacebookTwitterLinkedInGoogle+
Latest News
  • The final EPAD dataset is now available to the entire research community
    2020-11-30
  • ALZFORUM
    Alzforum conference blog mentions EPAD
    2020-11-30
  • EPAD v1500 dataset
    New webpage dedicated to EPAD data and samples on the EPAD website
    2020-11-18
  • ADDI launches new Workbench to foster greater global research innovation and accelerate breakthroughs in Alzheimer’s disease and related dementias
    2020-11-17
  • New paper investigating the prediction of Alzheimer’s disease biomarker status
    2020-11-12
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

We would like to thank all our followers! A massive thanks also goes to our research participants & members for all their support! Looking back on the years of the @IMI_EPAD project, here's key pictures took at major events. Have a safe & Happy New Year! youtu.be/FeYsOBOhCeo

reply retweet favorite
8:55 am · 2021-01-18
Twitter
EPAD
EPAD
@IMI_EPAD

The videos from #30AEC are online! Check out the @IMI_EPAD presentations on #data sharing by @rodrigobarnes (@aridhia) & Colin Veal (@uniofleicester). Thanks @IMI2_NEURONET and @AlzheimerEurope for giving us the opportunity to present our work. imi-neuronet.org/2020-virtual… twitter.com/IMI2_NEURONET/…

reply retweet favorite
8:43 am · 2021-01-15
Twitter
EPAD
EPAD
@IMI_EPAD

Authors investigated #data from nine studies, including @IMI_EPAD, comprising a total of 60,004 assessed participants. If you want to explore the #Alzheimer's disease data landscape, visit adata.scai.fraunhofer.de @BirkenbihlC @ApitiusHofmann @ddomingof @Simon_Lovestone @TVB_cloud

reply retweet favorite
7:56 am · 2021-01-11
Twitter
EPAD
EPAD
@IMI_EPAD

Numerous studies have collected #Alzheimer's disease cohort #data sets. @BirkenbihlC and colleagues have evaluated the Alzheimer's disease data landscape from a patient‐level data‐centric perspective. @IMI_EPAD @IMI_EMIF @NACCALZ alz-journals.onlinelibrary.wi…

reply retweet favorite
7:48 am · 2021-01-11
Twitter
EPAD
EPAD
@IMI_EPAD

The final @IMI_EPAD dataset is now available to the entire research community | News | @CORDIS_EU | European Commission europa.eu/!dj89jY

reply retweet favorite
12:55 pm · 2021-01-08
Copyright © 2015-19 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.